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Summary The increase of multi-drug resistant Pseudomonas aeruginosa infec-
tions is a worldwide dilemma. At the heart of the problem is the inability to treat
established P. aeruginosa bioﬁlms with standard antibiotic therapy, including ﬂu-
oroquinolones. We address a previously unstudied question as to the effect of a
commonly prescribed calcium channel blocker (CCB) diltiazem on the bioﬁlm growth.
Real-time monitoring of the overall growth and killing of P. aeruginosa bioﬁlm duringFluoroquinolone ﬂuoroquinolones therapy in the presence and absence of diltiazem was performed.
In this study, we demonstrate that for P. aeruginosa bioﬁlms, resistance to the ﬁrst-
line ﬂuoroquinolones may be induced by the commonly prescribed calcium channel
blocker diltiazem.
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iltiazem is a class III calcium channel blocker
CCB) belonging to benzothiazepines and has been
 This manuscript was presented in part at the Design of Med-
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pproved for the treatment of angina, hyper-
ension and cardiac arrhythmia [1]. It acts as
calcium antagonist that controls calcium ion
nﬂux in cardiac and vascular smooth muscle cells
hrough slow voltage-gated L-type channels in the
ell membrane. The stereoselective interaction of
iltiazem affects the binding domain of the 1
ubunit of L-type calcium channel. Diltiazem is a
otent vasodilator that is generally well-tolerated
1,2]. As such, it is a commonly used treat-
ent for elderly patients including those who are
iabetic [3].
g Saud Bin Abdulaziz University for Health Sciences. All rights reserved.
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Pseudomonas aeruginosa bioﬁlms account for a
signiﬁcant proportion of infections among catheter-
associated urinary tract infection (UTI) in long-term
care facilities, diabetic foot infections and lung
infections of cystic ﬁbrosis and other immunocom-
promised patients [3—7]. The bioﬁlm matrix affords
the bacteria protection from antibiotic penetration
leading to suboptimal treatment levels at the site
of infection and potentially inducing outgrowth of
resistant strains [8—10].
Fluoroquinolones, -lactams and aminoglyco-
sides are the three classes of antibiotics used
for treatment of P. aeruginosa infections. Unfor-
tunately, the multi-drug and pan-drug resistant
isolates of P. aeruginosa which patients are often
exposed to in the hospital setting are resis-
tant to one or more these three drug classes
[7,11—15]. Selective pressure due to excessive
exposure of bacteria to antibiotics is generally
cited as the cause for this high incidence of resis-
tance in a hospital environment. ICU and long-term
care facilities are also notorious worldwide for
harboring multi- and pan-resistant P. aeruginosa
strains [6,15,16]. However, the epidemiology of
community-acquired resistant strains is less clear
[7]. The causes or selective pressures behind
the generation of resistant strains become an
important question as our population ages and as
more immunocompromised patients survive and are
cared for in a community setting [17—20]. It is com-
mon for frail elderly patients to be on multiple drug
therapies including antibiotics. Detailed studies
regarding the induction of resistance by combina-
tions of antibiotics with other common medications
are rare to non-existent [21—23]. This work was
part of a large project designed to study the effect
of the co-administration of calcium channel block-
ers on ﬂuoroquinolone treatment of P. aeruginosa
bioﬁlm.
Materials and methods
Purchases were made from the following suppliers:
levoﬂoxacin, ciproﬂoxacin, norﬂoxacin, oﬂoxacin
and lomeﬂoxacin from Sigma—Aldrich (St. Louis,
MO). Diltiazem (MP Biomedicals, Solon, OH)
was purchased from Thermo-Fisher Scientiﬁc Inc.
(Waltham, MA). Moxiﬂoxacin was obtained from
Schering-Plough (Woodlands, TX). P. aeruginosa
ATCC27853 was purchased from the American Type
Culture Collection (Manassas, VA). Cultures were
prepared according to ATCC guidelines. All cell
culture media and supplements were purchased
from Thermo Fisher Scientiﬁc Inc. (Waltham, MA).
All antibiotic stock solutions and dilutions were
e
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repared according to the Clinical Laboratory
tandards Institute (CLSI) guidelines M7-A7 and
100-16.
Initial inocula of 1—3× 106 CFU/mL P. aeruginosa
ultures in the log phase were seeded into two
00-well polystyrene honeycomb plates. Bioﬁlms
ere allowed to develop in an incubator over 6 h
t 37 ◦C. Wells were washed carefully, once with
50L sterile saline, to remove planktonic cells.
ation-adjusted Mueller—Hinton II medium (MH)
ontaining diltiazem alone at 10mM or diltiazem
lus a ﬂuoroquinolone at two fold serial dilutions
ere added to the bioﬁlm cultures (250L/well
nal volume). Cell growth was monitored using the
ioscreen C (Growth Curves USA, Piscataway, NJ).
he Bioscreen C monitors microorganism growth by
easuring total turbidity of the liquid growth media
n each well. Changes in turbidity due to growth
r lysis of microorganisms are measured kinetically
ith a vertical photometrical technology through
he bottom of the well. A wide-band ﬁlter was used
o measure the turbidity. The wide-band ﬁlter is a
hite ﬁlter for turbidity measurement and its spec-
rum range is 420—580 nm. It is used in microbiology
esearch because its sensitivity is not affected by
ny color change of the medium.
Plates containing bioﬁlms treated with dilti-
zem (10mM) and ﬂuoroquinolones were placed
n the preheated incubating chamber of Bioscreen
which was programmed to maintain a temper-
ture of 37 ◦C. Optical density (OD) values were
btained at 1 h intervals over 96 h, without shaking.
rowth control wells contained bioﬁlms treated
ith Mueller—Hinton II broth only. Bioﬁlm was also
reated with MH medium spiked with increasing
oncentrations of D(+)-glucose (0.1—25mM) with-
ut diltiazem or antibiotics. Negative controls
ontaining MH alone and MH containing diltiazem
10mM) were involved in the experiments to check
or the sterility and absence of any precipita-
ions, respectively, within 96 h of incubation period.
ach bioﬁlm growth curve was repeated three
imes. The diltiazem concentration (10mM) was
hosen as the highest concentration that did not
nhibit bioﬁlm growth and did not precipitate from
he medium. Fluoroquinolone concentrations were
ithin the standard range used in CLSI protocols
o determine the minimum inhibitory concentration
MIC) for each ﬂuoroquinolone against planktonic
. aeruginosa. Data were automatically collected
y the Growth Curves software (EZExperiment) and
xported to an Excel spread sheet for processing.
IC is deﬁned as the concentration of ﬂuoro-
uinolone at which the OD remains at or returns to
aseline at the 24 h time point. Mutant prevention
oncentration (MPC) was reported as the antibi-
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tic value at 96 h that prevented the development
f resistant organisms [24]. Baseline OD readings
aken for all experiments was at approximately 0.2.
For visualization of P. aeruginosa bioﬁlm by con-
ocal scanning laser microscope (CSLM), the method
escribed by Walker et al. [41] was applied with
ome modiﬁcations. Brieﬂy, bioﬁlm of P. aerug-
nosa was grown as described for the control
n MH medium within 4-chambers culture slides
SuperCellTM Culture Slides, Fisher Scientiﬁc Inc.,
altham, MA). At 0 h and 12 h time points of bioﬁlm
ncubation, MH medium was carefully aspirated and
ulture slides were immersed in 5% (v/v) glutaralde-
yde (Fisher Scientiﬁc) in normal saline for 24 h for
xation and imparting ﬂuorescence for the bioﬁlm
ithout distortion of the bioﬁlm architecture. The
ncubating chambers of the culture slides were
arefully removed and each slide was rinsed with
0mL of PBS (Fisher Scientiﬁc). The bioﬁlms were
ounted with Citiﬂuor antifading (Sigma—Aldrich,
t. Louis). Each experiment was repeated twice
ith three replicates each and the slides were kept
t −20 ◦C till visualization using CSLM.
A series of images for P. aeruginosa bioﬁlm in
he z direction (z series) were digitized in selected
ptical planes with a CLSM Nikon TE2000 inverted
onfocal laser scanning microscope equipped with
ikon C1 laser scanning unit that provides laser
eams including Solid State Laser (405 nm), 480 nm
ichroic long pass ﬁlter, 450/35 nm band pass ﬁl-
er, Spectra Physics argon laser (488 nm), 545 nm
ichroic long pass ﬁlter, 515/30 nm band pass ﬁlter,
nd HeNe Laser (543 nm), 505/75 nm band pass ﬁl-
er (both instruments from Nikon Instruments Inc.,
elville, NY, USA). The system used a motorized
omputer-assisted device to control the vertical
ositioning during optical sectioning of the bioﬁlm.
mage scanning with the above mentioned lasers
as processed but the best images were obtained
ith argon laser (488 nm), 545 nm dichroic long pass
lter, 515/30 nm band pass ﬁlter using 1003/1.3
A Plan-Neoﬂuar lens. Images were generated by
pplying automated microscope image acquisition.
The morphological processor software (Nikon EZ-
1 software) on the attached computer enhanced
mages, discarded unwanted details, and acceler-
ted the colored-scale processing. Computerized
ixel calibration and image setup were deﬁned
elative to the calibration value used for image gen-
ration on the CLSM system. In this system, the size
nd position of the ‘‘area of interest’’ for manip-
lation were speciﬁed manually. The area covered
y microbial growth was scanned for each confo-
al plane relative to the thickness of the bioﬁlm
nd subsequently visualized at a 90◦ angle on the
btained images.
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esults
he ﬂuoroquinolone ciproﬂoxacin is a well-known
nti-pseudomonal that is rather commonly used for
TI in the elderly as well as for other P. aerug-
nosa infections [25,26]. CLSI expected range for
. aeruginosa ATCC27853 in the planktonic form
s 0.25—1g/mL. Bioﬁlm MIC values are gener-
lly expected to be anywhere from two fold to a
000× higher [10]. However, ciproﬂoxacin, in our
xperiments, showed a low MIC against P. aerug-
nosa bioﬁlm. In this study, we found an MIC of
.2—0.4g/mL depending on the time point, with
.4g/mL at 96 h reported as the MPC (Fig. 1A).
owever, when diltiazem (10mM) was added to the
edium with ciproﬂoxacin, an unusual growth pat-
ern developed. While the MIC might still have been
eported as 0.2g/mL at 24 h as the plate had been
ead by the naked eye, in fact, real-time monitor-
ng with the Bioscreen C allowed us to discern that
he culture is about to enter a log phase growth.
n the presence of the ciproﬂoxacin—diltiazem
ombination, all cultures showed an increase in
rowth up to four times that of the control at 96 h
Fig. 1B).
Most notable, however, was the unusual growth
attern exhibited by P. aeruginosa bioﬁlm in the
resence of diltiazem alone. In the presence of
iltiazem, the growth of P. aeruginosa bioﬁlm
reatly exceeded the control, showing an OD value
f about 2.4. This extraordinary growth pattern
ccurred consistently throughout all experiments
henever diltiazem was added and regardless of
he ﬂuoroquinolone tested (Fig. 1). The growth
romoting effect of diltiazem on P. aeruginosa
ioﬁlm was noticeable within the concentration
ange of 1—10mM (data not shown) in a dose
ependant manner. Nevertheless, we selected the
igher concentration level (10mM) to facilitate
onitoring the effect of diltiazem using Bioscreen
technology. Although higher concentrations of
uoroquinolones delayed the growth of P. aerug-
nosa bioﬁlm but none of the tested levels could
nhibit bioﬁlm growth by the end of the experi-
ents. Furthermore, this growth was maintained
n MH medium that otherwise might be consid-
red depleted in nutrients. The growth controls
nter log phase growth then drop to a plateau
f around OD 0.6 while the cultures contain-
ng diltiazem maintained plateau at OD 2.4. At
ime points >24 h, MICs for all ﬂuoroquinolones
ere increased over published CLSI mentioned
esistance levels when diltiazem was incorpo-
ated to the MH medium and no MPC values
ould be reported for any ﬂuoroquinolone at 96 h
Table 1).
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Figure 1 (A—L) represent real-time data for each set of experiments comparing treatment of Pseudomonas aeruginosa
bioﬁlm with a ﬂuoroquinolone alone and its companion experiment where diltiazem was present in addition to the
ﬂuoroquinolone. The MICs and MPCs for ﬂuoroquinolones are reported in g/mL. Figures (A, C, E, G, I and K) show MIC
at 24 h and MPC at 96 h for ﬂuoroquinolones alone against Pseudomonas aeruginosa bioﬁlm. Figures (B, D, F, H, J and L)
show MIC for each ﬂuoroquinolone with diltiazem against Pseudomonas aeruginosa bioﬁlm. No MPC could be reported.
Diltiazem concentration level in all experiments was 10mM. For clarity, some curves that overlay the growth control
were omitted.
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Figure 1 (Continued)
Table 1 Fluoroquinolone MICs at 24 h and MPCs at 96 h (g/mL) with and without diltiazem (10mM) added to
Mueller—Hinton medium for Pseudomonas aeruginosa ATCC27853 bioﬁlm.
Fluoroquinolone CLSI expected MIC Without diltiazem With diltiazem (10mM)
Planktonic MIC Bioﬁlm Bioﬁlm
24 h MIC 96 h MPC 24 h MIC 96 h MPC
Ciproﬂoxacin 0.25—1 0.2 0.4 0.2 >1.6
Levoﬂoxacin 0.5—4 2 4 2 >8
Lomeﬂoxacin 1—4 3.2 >3.2 3.2 >3.2
8 2 >16
2.5 5 >10
6.4 3.2 >12.8
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Figure 2 The effect of increasing concentrations of
glucose (0.1—25mM) added to the MH medium on the
growth of Pseudomonas aeruginosa bioﬁlm. There was
n
aMoxiﬂoxacin 1—8 2
Norﬂoxacin 1—4 1.25
Oﬂoxacin 1—8 3.2
Regarding the unusual growth curves, we won-
ered if diltiazem might be acting as a surrogate
arbon source in depleted MH medium. To deter-
ine if simply providing increased nutrients could
ave such an effect on the growth curve, cultures
ere prepared as for the diltiazem and ﬂuoro-
uinolone experiments but adding only increasing
oncentrations of glucose (0.1—25mM) to the MH
edium. Although increased glucose level in the
H medium slightly increased the OD at which
he growth curve reached a plateau, no signiﬁcant
hanges in the OD of the curve peak was observed
ven with the highest tested glucose concentration
25mM). Furthermore, the maximum growth was
aintained at OD 1.3 or less (Fig. 2).
For visualization of the growth for the estab-
ished P. aeruginosa bioﬁlm, CSLM technique was
pplied and the results (Fig. 3a and b) showed
arked increase in the bioﬁlm growth (cell count
nd bioﬁlm depth) within 12 h as compared to 0 h
ncubation.
D
T
to signiﬁcant effect on the growth curve of Pseudomonas
eruginosa bioﬁlm.iscussion
here is a pressing need for a deeper and more
horough understanding of the mechanisms that
110
Figure 3 (a) Optical sectioning produced by CLSM, illus-
trating the horizontal colonization of P. aeruginosa at
different bioﬁlm depths at the beginning of the exper-
iment (0 h of incubation). Scale bar = 10m. In some
cases, images were affected by light reﬂections at the
position closest to the substratum. (b) Optical sectioning
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tion of resistance. We need to reappraise manyproduced by CLSM, illustrating the horizontal coloniza-
tion of P. aeruginosa at different bioﬁlm depths at 12 h of
incubation. Scale bar = 10m.
lie behind the selection and development of MDR
and PDR pathogens especially within bioﬁlms. P.
aeruginosa is a ﬁerce environmental organism, well
designed to withstand attacks by other bacte-
ria, fungi, amoebas and disinfectants [4]. Since it
comes pre-equipped with the machinery for pan-
drug resistance, selection of resistant strains occurs
quickly and often as evidenced by outbreaks of MDR
and PDR P. aeruginosa in health facilities around the
globe [6,11,14,19,27—33].
Here we present an argument for detailed
studies regarding the potential for commonly pre-
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cribed drugs to ‘‘preselect’’ drug resistant strains,
nduce changes in growth rate and/or encour-
ge resistance. In this instance, we assessed
iltiazem—ﬂuoroquinolones combinations in vitro
sing real-time monitoring of effects of such com-
inations on the bioﬁlm growth using Bioscreen C.
lthough the CLSM images showed marked growth
or P. aeruginosa bioﬁlm, but it has to be taken
nto consideration that OD readings obtained from
ioscreen C represent the overall growth of both
ioﬁlm and the shedding planktonic cells from that
ioﬁlm. While there are rare references on the
otential antibacterial activities of verapamil and
mlodipine on planktonic bacteria [34—36], there
s no previous evidence, of which we are aware,
hat describes the effect of diltiazem on P. aerug-
nosa bioﬁlms and the resultant resistance of this
rganism to the most important antibiotic class, ﬂu-
roquinolones, used for its treatment. The results
evealed that the diltiazem inducing resistance
or P. aeruginosa bioﬁlm against ﬂuoroquinolones
as not through carbon source enrichment for the
edium. Eickelberg et al. [42] demonstrated that
iltiazem is capable of activating expression of
ome genes and it may directly regulate cellular
unctions by affecting the activity of transcrip-
ion factors independently of intracellular calcium
oncentrations. Since divalent cations, particularly
alcium, are important bridging ions for bacte-
ial polysaccharides, bioﬁlm formation and they
lay regulatory roles in bacterial gene expres-
ion [43], the agents that affect calcium binding
ay also inﬂuence the gene expression. Therefore,
he observed diltiazem effect in this study might
e through transcription up-regulation of some P.
eruginosa genes including parC, gyrA, quorum
ensing system, or alteration in size and expression
f different porins. Consequently, further studies
re required to elucidate the possible mechanism(s)
f resistance.
The study of bioﬁlms as they relate to chronic
nfections is a burgeoning ﬁeld. The founders of
ioﬁlm study began by studying bioﬁlms of P. aerug-
nosa in the environment [37,38]. As years passed,
t became clear that bioﬁlms must also play a sig-
iﬁcant role in human infection as well as to the
mergence of resistant bacterial diseases [39—41].
ven as we are only beginning to understand this
orm of growth and its attendant survival mech-
nisms that relate to antibiotic resistance, we
ust broaden the scope of our view on induc-rugs as potential catalysts for the selection of
esistance. We must begin to reevaluate commonly
rescribed drugs like calcium channel blockers for
ts potential microbiological interaction. It might
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e essential to reassess several drug-antibiotic co-
dministration scenarios that we once thought to
e safe because, for example, there is no interfer-
nce through metabolic mechanisms in the human
ody. We must currently reappraise the effect of
on-antibiotic drugs on the infectious microorgan-
sms especially when co-prescribed with the drugs
e use to eradicate those organisms. While this
nvestigative area appears overwhelming, it may
e imperative when one considers the potential for
ositive as well as negative effects.
onclusion
e have clearly described the effect of diltiazem
n the overall growth of P. aeruginosa bioﬁlm. This
nusual growth pattern cannot be induced sim-
ly by adding additional nutrient to the medium.
urther studies are required to clarify the mech-
nism underlying the resistance of P. aeruginosa
ioﬁlm to ﬂuoroquinolones in the presence of dil-
iazem. Moreover, combination of diltiazem with
uoroquinolones for patients suffering from P.
eruginosa infections, e.g. cystic ﬁbrosis patients,
s a concomitant prescription therapy may be con-
raindicated from a microbiological point of view.
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